Clinical Trial Update: Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rasburicase for treatment/prevention of hyperuricemia in adults with relapsing aggressive non-Hodgkin lymphoma; status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperuricemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Rasburicase (rasburicase)

Snippet

Sponsor: Sanofi | Conditions: Hyperuricemia | Phase 2 | Status: TERMINATED